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Background. Despite the recognized benefit of antiretroviral therapy (ART) for preventing and treating HIV, some studies have 
reported adverse birth outcomes with in utero ART exposure. We evaluated the effect of infant in utero HIV and ART exposure on 
preterm delivery (PTD), low birth weight (LBW), small for gestational age (SGA), and underweight for age (UFA) at 6 weeks.
Methods. We surveyed 6179 HIV-unexposed-uninfected (HUU) and 2599 HIV-exposed-uninfected (HEU) infants. HEU infants 
were stratified into 3 groups: ART, Zidovudine alone, and no antiretrovirals (None). The ART group was further stratified to explore 
pre- or postconception exposure. Multivariable logistic regression evaluated effects of HIV and ARV exposure on the outcomes.
Results. We found higher odds of PTD, LBW, SGA, and UFA in HEU than HUU infants. HEU in the None group (adjusted 
odds ratio [AOR], 1.9; 95% confidence interval [CI], 1.2–3.0) or those whose mothers initiated ART preconception (AOR, 1.7; 95% 
CI, 1.1–2.5) had almost twice the odds of PTD than infants whose mothers started ART postconception, but no increased odds for 
other outcomes.
Conclusions. There was an association between preconception ART and PTD. As ART access increases, pregnancy registers or 
similar surveillance should be in place to monitor outcomes to inform future policy.
Keywords. antiretroviral therapy; birth outcome; HIV; South Africa.
 
With the success of the Prevention of Mother To Child HIV 
Transmission (PMTCT) program, HIV-exposed-uninfected 
(HEU) children now constitute the majority of the children 
affected by the HIV pandemic [1]. In January 2015, South Africa 
(SA), which has a antenatal HIV prevalence of 29%, adopted 
the 2013 World Health Organization (WHO) recommendation 
of lifelong antiretroviral treatment (ART) for all HIV-positive 
pregnant women, referred to as WHO-PMTCT Option-B+, as 
a PMTCT strategy to maintain maternal health [2, 3]. Although 
the benefits of ART outweigh the potential adverse effects, 
this population of HEU children requires monitoring to bet-
ter understand the short- and long-term health effects of HIV 
and ART exposure [4]. The shift to Option-B+, and the possi-
ble future use of pre-exposure prophylaxis (PreP) as a primary 
prevention method in HIV-uninfected adolescents and young 
women [5, 6], will increase the number of children exposed to 
ART during critical intrauterine, intrapartum, and postpartum 
periods. It is well established that HIV infection in children is 
associated with poor birth [7] and postnatal [8–10] outcomes. 
However, the effect of exposure to maternal HIV infection and 
ART use on the birth outcomes of HEU infants in resource-lim-
ited settings, where HEU children have a higher mortality risk 
than HUU children [11] and where endemic undernutrition 
and co-infections can compound any potential adverse effect of 
HIV or ART exposure, is less clear. Using data from a nation-
ally representative facility-based PMTCT survey, we studied 
the effect of infant in utero HIV and ART exposure on preterm 
delivery (PTD), low birth weight (LBW), small for gestational 




The 2012–13 South African PMTCT Evaluation (SAPMTCTE) 
was a nationally representative facility-based cross-sectional 
survey, conducted between October 2012 and May 2013, to 
measure vertical HIV transmission at 4–8 weeks postpartum. 
During this study, ART use was criteria-led (WHO PMTCT 
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“Option-A”), changing to “universal test and treat” for all 
HIV-positive pregnant women throughout breastfeeding 
(“Option-B”) in April 2013. Under Option-A, antiretroviral 
drug (ARV)-naïve HIV-infected pregnant women were placed 
on ART (recommended tenofovir disoproxil fumarate [TDF] 
+ [3TC]/Emtracitaine [FTC] + Nevirapine [NVP]) if CD4 cell 
count ≤350 cells/mm3 or Zidovudine (ZDV) from 14 weeks ges-
tation (with infant NVP for 6 weeks or until 1 week postbreast-
feeding) if CD4 >350 cells/mm3 [12].
The study methods have been described elsewhere [13] and 
are summarized in the Supplementary Materials. In brief, 580 
primary health facilities offering immunization services were 
sampled using a probability proportional to size approach. 
Consenting mother-infant pairs attending immunization ser-
vices were consecutively or systematically enrolled, regardless of 
maternal HIV status, in each facility. Sick infants needing emer-
gency care and those aged <4 weeks or >8 weeks were excluded.
Exposure Measures
Maternal HIV infection and ART use were the primary expo-
sures. Trained nurse data collectors drew infant dried blood 
spot (iDBS) specimens during the study visits. All iDBS received 
HIV antibody (serological) testing, and antibody-positive sam-
ples or samples from self-reporting HIV-positive mothers were 
tested for both HIV-1 proviral DNA and HIV-1 RNA (see 
the Supplementary Methods). Data collectors used electronic 
questionnaires to gather self-reported data on the mother’s 
drug use and timing of initiation. As no maternal blood speci-
mens were collected, a mother was defined as HIV-negative if 
the infant’s antibody result was negative and HIV-infected if 2 
infant HIV antibody test results were positive. An infant was 
defined as HEU if (1) the HIV antibody result was positive and 
polymerase chain reaction (PCR) result was negative or (2) the 
antibody result was positive and PCR equivocal or rejected (1% 
of sample), or HUU if both results were negative. Among HIV-
infected mothers, self-reported ARV use was categorized into 
3 groups: namely (1) ART use primarily for mother’s health 
(ART-group), as per Option-A guidelines, (2) antenatal ZDV 
as MTCT prophylaxis (ZDV-group), and (3) no ARV use 
antenatally (None group). Given that ART, particularly TDF, 
which has been associated with poor birth outcomes, has low 
bioavailability in breastmilk [14], infants whose mothers only 
started ART postnatally were excluded from this analysis. In an 
effort to (1) make the periods of exposure to ARV drugs com-
parable between women on ZDV versus ART and (2) compare 
outcomes by duration of ART exposure, women on ART were 
further dichotomised by ART duration, and those who initiated 
ART postconception were treated as the reference.
Outcomes
The outcomes of interest were PTD, LBW, SGA at birth, and 
UFA at 6 weeks postpartum. Birth weight and length, 6-week 
weight and length, and gestational age were extracted from the 
infants’ routine road to health booklets at 4–8 weeks (median, 
6 weeks) postpartum. The anthropometric measurements were 
conducted by routine health facility staff using facility proce-
dures and equipment. Length data were excluded in this analysis 
due to measurement errors and missing data. Health facility staff 
routinely estimated infant gestational age at delivery using the 
last menstrual period (LMP). PTD was defined as birth before 
37 completed weeks gestation, LBW as birthweight <2.5 Kg, 
and SGA as birthweight-for-gestational-age z score below –1.28 
(equivalent to <10th percentile) [15, 16]. We estimated birth-
weight-for-gestational-age z scores using recently published 
international Intergrowth-21st standards for assessing newborn 
size for term- and preterm-born infants [17] and LMS growth 
[18]. We estimated weight-for-age z scores (WAZ) in infants age 
4–8 weeks using the WHO growth standards [19] and consid-
ered infants to be UFA if their WAZ was below –2 [20].
Data Cleaning
Anthropometric measurements and z scores were flagged for 
verification if any of the following criteria were met: birth-
weight-for-gestational z score <–6 or >6; WAZ less than –6 or >5. 
Except for gestational age, which had 1% observations set to miss-
ing after verification (including 3 gestational ages outside of the 
range for the Intergrowth standards [20–23 weeks]), the remain-
ing measurements and z scores had <1% observations omitted.
Covariates
Covariates in the models were selected a priori based on the lit-
erature [21] and a conceptual framework (Supplementary Figure 
1). Participants were defined as food insecure if they ever ran out 
of food in the previous year. Multiple correspondence analysis 
(MCA) was used to to construct the socio-economic status (SES) 
index (see the Supplementary Materials). Infant feeding practices 
were established through 8-day recall infant feeding questions, 
and infants were categorized into 2 groups: (1) “breastfed” if they 
received any breastmilk and (2) “non-breastfed” if they received 
no breastmilk. As SA has historical racial inequalities, race was 
included in the models as a potential social determinant of the 
study outcomes [22]. Based on the reported race, study infants 
were classified as (1) “black,” (2) “colored,” a multiracial group, 
or (3) “other,” comprised of very small samples of infants defined 
as “white,” “indian,” and “other.”
Statistical Analysis
Analyses were survey based, and additional weighting for 
missing gestational age data was applied to the PTD and SGA 
analyses (see the Supplementary Materials). Categorical var-
iables were compared using the Pearson chi-square test while 
linear regression was used to test equality of means. The Wald 
test was used for multiple hypothesis testing. In the modeling, 
we first generated 4 multivariable logistic regression models 
to assess the effect of in utero HIV exposure on outcomes in 
the total sample of HUU and HEU infants. We then restricted 
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ART exposure status and duration using 4 additional models. 
To avoid bias introduced by adjustment of potential mediators 
in the presence of unmeasured common causes, the “LBW par-
adox” [23], variables such as birthweight were not included in 
the UFA models. In each full model, we also included interac-
tion terms to test whether infant HIV exposure modifies the 
effect of other covariates on birth outcomes. Statistical anal-
yses were performed at a 5% significance level using STATA-
14 (Stata Corp., College Station, Texas), R Software-3.1.2, and 
IBM-SPSS Statistics-22 (SPSS Inc, Chicago, Illinois).
Ethical Considerations
Ethical approval was obtained from the South African Medical 
Research Council and the Office of Associate Director of 
Science at the US Centers for Disease Control and Prevention. 
All participants provided informed consent.
RESULTS
There were 9119 live-born infants in the SAPMTCTE study, 
of which 8975 were of a singleton birth (Figure 1). The final 
sample analyzed included 6179 HUU and 2599 HEU infants. 
Notably, women who initiated ART preconception were older, 
had a higher parity, and higher frequencies of TB and syphilis 
than women in the other ARV groups (Table 1).
Prevalence of PTD, LBW, SGA, and 6-Week Childhood Underweight
The prevalences of PTD, LBW, and SGA were 12.5% (95% confi-
dence interval [CI], 11.4–13.7%), 10.7% (95% CI, 10.0–11.5%), 
and 14.9% (95% CI, 13.8–16.1%), respectively, in the total sam-
ple (Table 2). The prevalence of PTD was similar between HUU 
(12.3%; 95% CI, 11.1–13.7%) and HEU (12.9%; 95% CI, 11.12–
14.7%) infants (P = .59) in the unadjusted analysis, whereas the 
latter group had a higher prevalence of LBW (13.0% vs 9.8%; P 
< .01) and SGA (16.9% vs 14.0%; P = .03). UFA at 6 weeks post-
partum was observed in 9.2% (8.6%; 10.0%) of the total sam-
ple. A higher proportion of infants were underweight in HEU 
(11.0%) versus HUU (8.4%) infants (P < .01).
Factors Related to PTD, LBW, and SGA
Multivariable analyses demonstrated a higher odds of PTD if 
the infant was HEU versus HUU (adjusted odds ratio [aOR], 
1.2; 95% CI, 1.0–1.5), was of colored versus black race (aOR, 
1.7; 95% CI, 1.3–2.3), was born to a mother with less than a 
secondary education (aOR, 1.4; 95% CI, 1.1–1.7), and resided 
in a poorer household (aOR, 1.7; 95% CI, 1.2–2.5). There was 
a reduced odds of PTD if the infant was born to a mother age 
30–35 years versus <20 years (aOR, 0.7; 95% CI, 0.5–0.9) and 
had more than 5 antenatal care (ANC) visits versus ≤5 (aOR, 
0.7; 95% CI, 0.6–0.9) (Table 3). Within the HEU subgroup, 
infants in the None group (aOR, 1.9; 95% CI, 1.1–3.1) or those 
whose mothers initiated ART preconception (aOR, 1.7; 95% CI, 
1.1–2.5) had almost twice the odds of PTD than infants whose 
mothers initiated ART postconception.
A higher odds of LBW was observed if an infant was HEU ver-
sus HUU (aOR, 1.6; 95% CI, 1.3–1.9), born to a mother with TB 
during pregnancy (aOR, 1.6; 95% CI, 1.1–2.5), and if the infant 
was of colored versus black race (aOR, 2.0; 95% CI, 1.5–2.6), was 
born to a mother with less than a secondary education (aOR, 
1.3; 95% CI, 1.0–1.6), and resided in a poorer household (aOR, 
1.5; 95% CI, 1.1–2.0); a reduced odds of LBW was observed if 
the infant was born to an older mother versus a mother age <20 
years (aOR, 0.6; 95% CI, 0.5–0.8), a mother who had more than 5 
versus ≤5 ANC visits (aOR, 0.8; 95% CI, 0.6–0.9), or if the infant 
was male versus female (aOR, 0.8; 95% CI, 0.7–0.9) (Table 4).
A higher odds of SGA was observed if an infant was HEU 
versus HUU (aOR, 1.3; 95% CI, 1.1–1.6) and born of colored 
versus black race (aOR, 1.6; 95% CI, 1.3–2.0). Factors protective 
against SGA were older maternal age (aged 26–29) versus aged 
<20 years (aOR, 0.6; 95% CI, 0.4–0.8) and attendance of 5 ver-
sus ≤5 ANC visits (aOR, 0.8; 95% CI, 0.7–1.0) (Table 5).
Factors Related to UFA at 6 Weeks Postpartum
A greater odds of UFA at 6 weeks postpartum was observed if an 
infant was HEU versus HUU (aOR, 1.5; 95% CI, 1.2–1.8), if colored 
versus black race (aOR, 2.2; 95% CI, 1.6–2.8), was born by caesar-
ean section (C-section) versus vaginal delivery (aOR, 1.4; 95% CI, 
1.1–1.7), had experienced diarrheal episodes in the first 6 weeks of 
life (aOR, 1.9; 95% CI, 1.3–2.8), was born to mother who had TB 
during pregnancy (aOR, 1.8; 95% CI, 1.2–2.8) or had less than a 
secondary education (aOR, 1.4; 95% CI, 1.1–1.8) and resided in a 
poorer household (aOR, 1.5; 95% CI, 1.1–2.0). A reduced odds of 
UFA was observed if the infant was breastfed versus not breastfed 
(aOR, 0.8; 95% CI, 0.6–1.0) and if the infant was born to a mother 
who attended more than 5 ANC visits versus ≤5 (aOR, 0.8; 95% CI, 
0.6–1.0) (Table 6). None of the models showed evidence of effect 
measure modification by HIV exposure status (data not shown).
DISCUSSION
In a nationally representative survey, we observed greater odds 
of PTD, LBW, SGA, and UFA among HEU than HUU infants.
We observed that HEU infants whose mothers did not receive 
ARVs carried higher odds of PTD than postconception ART-
exposed infants but no increased odds for LBW, SGA, and 
underweight. In addition, among ART-exposed pregnancies, 
PTD was more common among infants whose mothers initi-
ated ART preconception than postconception. We also identi-
fied several independent risk factors for poor birth and growth 
outcomes, including colored race, which was associated with all 
study outcomes; birth by C-section, which was associated with 
UFA; exposure to maternal TB during pregnancy, which was 
associated with LBW and UFA; and diarrhea was a risk factor 
for UFA; a lower maternal education and household SES, which 
were associated with PTD, LBW, and UFA. Factors that were 
protective against all outcomes included older maternal age and 
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included male gender for LBW and UFA and breastfeeding for 
UFA.
Our finding that HEU infants have more adverse birth out-
comes than HUU infants has been reported in other African 
studies (Supplementary Table  2) [24]. Within SA, data from 
a hospital-based cohort study in the Western Cape showed 
a higher prevalence of PTD and LBW, but not SGA, in HIV-
exposed versus HUU infants [25]. Surveillance pregnancy reg-
istry data in KwaZulu-Natal also showed a higher prevalence of 
LBW in HIV-exposed than HUU infants [26]. Another cohort 
10 533 Screened
9880 (93.8%) Eligible
9679 (98.0%) Caregiver consented
9631 (99.50%) Interviewed + iDBS consent
9201 (95.53%) Interview + iDBS available
9119 (99.11%) Interview + iDBS available
430 (4.5%) No iDBS result available
70 (0.8%) iDBS Rejected by lab
Excluded:
80 Multiple births
67 HIV infected infants
31 infants-mum started ART postpartum
99 infants with no ARV information
2876 ELISA positive 6243 ELISA negative
6179 singleton HUU infants
Excluded:
64 Multiple births
2599 singleton HEU infants
Birth weight: 2531
6-week weight: 2443 6-week WAZ: 2440
GA: 1845 Birth Z-score: 1819 Birth weight: 6042
6-week weight: 5842 6-week WAZ: 5842
GA: 4380 Birth Z-score: 4333
47 (0.48%) Mother refused DBS
201 (2.0%) Refusals
652 (6.2%) Not eligible
184: Missing info on consent & DTP
132: Child needed emergency care
136: Chile <4wks or >8wks
200: Child did not receive DTP
383: Specimen lost in transit
21: Insucient specimen not sent to lab
26: Blood specimen not taken
1 (0.01%) Mother refused interview
Figure 1. The 2012–13 South African Prevention of Mother To Child HIV Transmission Evaluation study profile. Abbreviations: ART, antiretroviral treatment; ARV, antiret-
roviral drug; DTP, diphtheria, tetanus and pertussis; ELISA, enzyme-linked immunosorbent assay; GA, gestational age; HEU, HIV exposed uninfected infants; HUU, HIV unex-
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Table 1. Weighted Analysis of Participant Characteristics by HIV and Antiretroviral Exposure Status
Characteristics
HUU (n = 6179), % 
(95% CI)
 HEU (n = 2599)
Total (n = 8778),  
% (95% CI)
Preconception ART 
(n = 616), % (95% CI)
Postconception ART 
(n = 780), % (95% CI)
ZDV (n = 873), % 
(95% CI)
None (n = 330), % 
(95% CI)
Maternal
Age at enrollment, y
 <20 18.3 (17.1–19.6) 1.8 (1.0–3.2) 3.1 (2.0–4.9) 7.0 (5.0–9.6) 5.2 (3.2–8.4) 14.0 (13.1–15.0)
 20–25 39.6 (38.2–41.1) 10.0 (7.8–12.8) 28.5 (25.2–32.0) 36.2 (32.6–40.0) 34.9 (29.0–41.3) 35.9 (34.7–37.1)
 26–29 17.9 (16.8–19.0) 23.3 (19.7–27.2) 27.2 (24.1–30.5) 26.1 (23.1–29.4) 24.5 (19.7–30.1) 20.3 (19.3–21.3)
 30–35 14.0 (12.9–15.1) 35.2 (31.1–39.4) 29.8 (26.5–33.3) 19.1 (16.5–22.0) 20.7 (16.2–26.0) 17.5 (16.5–18.5)
 >35 10.0 (9.1–10.9) 29.8 (26.5–33.3) 14.6 (12.0–17.7) 11.6 (9.5–14.0) 14.7 (10.8–19.7) 12.2 (11.4–13.0)
 Missing 0.3 (0.2–0.5) 0 0 0 0 0.2 (1.0–3.0)
Parity
 1 43.0 (41.7–44.4) 15.4 (12.5–18.8) 24.8 (21.7–28.2) 30.6 (26.7–34.7) 24.1 (19.2–29.7) 37.3 (36.1–38.4)
 2–3 44.4 (43.0–45.7) 63.6 (59.5–67.6) 65.0 (61.2–68.6) 58.8 (54.7–62.8) 63.7 (57.6–69.3) 50.0 (48.8–51.1)
 4+ 8.54 (7.8–9.3) 21.0 (17.6–24.9) 10.2 (8.1–12.9) 10.64 (8.7–13.0) 12.3 (8.9–16.7) 10.0 (9.3–10.7)
 Missing 4.1 (3.5–4.7) 0 0 0 0 2.8 (2.4–3.3)
Education (grade)
 ≤grade 7 11.0 (10.0–12.2) 16.9 (14.8–19.2) 15.1 (12.6–17.9) 21.8 (17.3–27.1) 22.1 (15.0–31.3) 12.9 (11.9–14.0)
 >grade 7 88.7 (87.5–89.7) 83.1 (80.8–85.2) 85.0 (82.1–87.4) 78.2 (72.9–82.7) 74.5 (64.9–82.3) 82.9 (81.1–84.6)
 Missing 0.3 (0.2–0.5) 0 0 0 0 0.2 (0.1–0.4)
Delivery mode
 Vaginal 76.8 (75.4–78.1) 71.3 (66.9–75.3) 73.2 (69.3–76.8) 76.8 (73.5–79.9) 78.0 (71.9–83.1) 76.1 (74.7–77.4)
 C-section 23.1 (21.8–24.4) 28.7 (24.7–33.1) 26.5 (22.9–30.4) 23.2 (20.1–26.5) 21.9 (16.8–28.0) 23.8 (22.5–25.1)
 Missing 0.2 (0.1–0.3) 0 0.3 (0.1–1.1) 0 0.1 (0.0–0.8) 1.5 (0.8–2.8)
ANC visits
 1–5 44.6 (42.2–47.2) 41.9 (40.0–47.0) 38.0 (32.8–43.5) 39.2 (35.2–43.3) 48.4 (42.3–54.6) 43.4 (41.0–45.8)
 5+ 23.4 (21.1–25.8) 31.7 (26.6–37.3) 28.7 (24.4–33.5) 26.91(23.1–31.1) 21.7 (16.8–27.6) 24.8 (22.5–27.2)
 Missing 32.0 (29.2–34.9) 26.4 (21.8–31.5) 33.3 (27.6–39.4) 33.9 (28.7–39.6) 29.9 (24.0–36.5) 31.8 (29.0–43.8)
Syphilis during 
pregnancy
 Positive 1.1 (0.8–1.5) 8.1 (4.8–13.1) 7.6 (4.6–12.2) 4.6 (2.9–7.1) 2.6 (1.3–5.1) 2.7 (2.0–3.6)
 Negative 68.3 (65.5–71.0) 64.9 (59.0–70.4) 66.8 (61.3–71.8) 70.4 (66.4–74.2) 58.1 (51.4–64.5) 67.8 (65.1–70.3)
 Missing 30.6 (28.0–33.4) 27.1 (22.2–32.6) 25.7 (21.4–30.4) 25.0 (21.4–28.9) 39.24 (32.89–46.0) 29.6 (27.1–32.2)
Tuberculosis during 
pregnancy
 Yes 1.3 (1.0–1.6) 9.5 (7.1–12.5) 5.1 (3.4–7.5) 2.2 (1.2–4.1) 1.89 (0.75–4.73) 2.4 (2.0–2.8)
 No 94.5 (93.7–95.2) 90.0 (87.0–92.4) 94.4 (91.7–96.2) 97.6 (95.7–98.7) 97.88 (95.07–99.10) 94.6 (93.9–95.2)
 Missing 4.2 (3.7–4.9) 0.5 (0.1–1.6) 0.5 (0.2–1.4) 0.1 (0.0–0.7) 0.23 (0.03–1.61) 3.0 (2.6–3.5)
No food 14.0 (12.4–15.7) 18.6 (15.4–22.2) 14.9 (10.4–20.8)
Household socio- 
economic quintile
 Poorest 15.2 (13.5–17.0) 16.5 (13.4–20.2) 15.1 (12.4–18.2) 16.3 (13.5–19.6) 21.6 (17.0–27.0) 15.6 (14.0–17.4)
 Second 16.9 (15.4–18.6) 17.6 (14.3–21.5) 21.0 (17.8–24.7) 20.9 (17.8–24.3) 18.0 (13.9–23.0) 17.8 (16.3–19.4)
 Third 17.8 (16.4–19.3) 20.5 (17.2–24.2) 21.3 (17.9–25.1) 23.0 (19.4–27.0) 24.0 (19.4–29.3) 19.1 (17.8–20.5)
 Fourth 35.8 (33.5–38.1) 35.2 (30.9–39.7) 34.1 (29.6–35.2) 30.6 (26.3–35.2) 28.1 (22.9–33.9) 34.7 (32.6–37.0)
 Least poor 14.3 (12.8–16.0) 10.2 (7.5–13.8) 8.6 (6.5–11.2) 9.3 (7.0–12.2) 8.4 (4.6–14.7) 12.7 (11.4–14.2)
 Missing 0 0 0 0 0 0
Infant
 Male 51.4 (50.0–52.7) 50.5 (46.2–54.8) 48.5 (44.2–52.8) 54.8 (51.2–58.4) 51.8 (46.1–57.4) 51.4 (50.3–52.6)
Race
 Black 85.7 (83.0–88.1) 97.3 (94.9–98.5) 98.2 (97.1–99.0) 96.2 (94.1–97.5) 97.5 (94.5–98.9) 89.3 (87.2–91.1)
 Colored 12.6 (10.4–15.2) 2.7 (1.5–5.1) 1.8 (1.0–3.0) 3.3 (2.0–5.3) 2.0 (0.9–4.7) 9.5 (7.8–11.5)
 Other 1.7 (1.1–2.6) 0 0 0.6 (0.2–1.9) 0.5 (0.1–3.5) 1.3 (0.8–1.9)
Breast feeding
 Yes 88.0 (86.9–89.1) 58.2 (52.5–63.6) 62.8 (59.1–66.4) 65.7 (62.2–69.0) 73.0 (66.7–78.6) 80.6 (79.3–81.8)
 No 12.0 (10.9–13.1) 41.8 (36.4–47.5) 37.2 (33.6–40.9) 34.3 (31.0–37.8) 27.0 (21.4–33.3) 19.4 (18.2–20.7)
Abbreviations: ART: antiretroviral treatment; CI: confidence interval; HEU: HIV-exposed uninfected infants; HUU: HIV-unexposed infants; LBW: low birthweight; None: infant was not 
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study in the same region reported a higher prevalence of SGA but 
not PTD in HIV-exposed infants [7]. The mechanisms through 
which maternal HIV infection results in specific adverse birth 
outcomes in HEU infants are still unclear. Current evidence 
suggests that HIV exposure elicits chronic immune activation 
and systemic inflammation in HEU infants [27, 28], particularly 
in infants born to women with higher viral loads [29], which 
have been associated with PTD [30, 31] and LBW [31]. These 
proposed mechanisms may partly explain why, similar to other 
studies [32, 33], our study infants born to women with untreated 
HIV infection had higher rates of PTD compared with infants 
born to women who initiated ART during pregnancy. These 
results support the current “test and treat” strategy of initiating 
all newly diagnosed HIV-positive pregnant women on ART.
However, exposure to ART during pregnancy, a critical 
period of fetal growth and development, may carry some risks. 
Evidence on the effect of in utero ART exposure on adverse out-
comes is mixed (Supplementary Table 2) [34], and there is still 
uncertainty as to whether observed adverse effects are specific 
to particular drugs or combinations thereof. Moreover, as more 
countries adopt the Option-B+ strategy, many more women will 
be on ART drugs at conception, highlighting the importance of 
setting up pregnancy registers or similar surveillance systems to 
monitor whether earlier ART initiation adversely affects birth 
outcomes in order to inform future policy. Such monitoring fits 
into the broader child health goals of reducing child mortality 
while optimizing good health and well-being [35]. Consistent 
with findings from a recent review [36], our data show that PTD 
is higher among women who initiated ART preconception than 
among mothers initiating ART postconception. These findings 
are in contrast to the null associations reported in single-site 
hospital-based retropective [37] and prospective [25] cohort 
studies conducted in SA and could be biased by the unmeas-
ured maternal disease severity or could be due to selection bias 
[38]. In line with these studies, however, LBW and SGA did not 
differ by timing of ART initiation in our sample.
The success of PMTCT programs make it possible for most 
HIV-exposed infants to remain uninfected [1]. Therefore, while 
the proportion of under-5 deaths attributed to HIV infection has 
decreased in SA, the proportion of under-5 deaths due to neona-
tal conditions has increased. Given that PTD complications con-
stitute the bulk of these neonatal conditions, it is important that 
risk factors for PTD are addressed through better care of both 
mothers and infants [39, 40]. Our findings that older mater-
nal age and more frequent ANC visits were protective against 
all adverse study outcomes, and that infants born to women 
with lower maternal education and SES had a greater risk for 
PTD, LBW, and UFA, highlight the importance of health system 
strengthening and the need for further investment in multisec-
toral “nutrition-sensitive” interventions [41] that address the 
multifactorial etiology of these outcomes. The protective effect 
of breastfeeding on childhood UFA further emphasizes the 
importance of supporting early initiation of breastfeeding for all 
infants.
Our study describes birth outcomes in infants that survived 
their first month of life; therefore, our overall LBW rate is lower 
than the national estimate of 14.8%, which is based on data 
from all live births [42]. Background national estimates of PTD 
and SGA are not readily available in South Africa. Our PTD rate 
was higher than the 8.0% modeled by Blencowe et al. [43] based 
on data from 2 hospital-based studies, while our SGA rate is 
lower than the 23% and 21.8% reported by Lee et al. [44] among 
preterm- and term-born infants, respectively.
This study has some limitations. First, we were limited by the 
lack of key clinical data, such as maternal obstetric history, sub-
stance use, accurate CD4 cell count, HIV viral load, and whether 
or not the PTD was induced or spontaneous. While data col-
lectors used a chart to help HIV-infected mothers recall their 
self-reported ARV drug use, which is subject to recall bias and 
may cause misclassification of participants, the lack of detailed 
information on the specific drug and dose used precluded 
the extent to which study outcomes could be assessed by ART 
Table 2. Adverse Birth and Growth Outcomes by HIV and ARV Exposure Status
 Group PTD, n [% (95% CI)] LBW, n [% (95% CI)] SGA, n [% (95% CI)] UFA, n [% (95% CI)]
HUU n = 6179 568 [12.3 (11.1–13.7)] 624 [9.8 (8.9–10.7)] 590 [14.0 (12.8–15.4)] 531 [8.44 (7.7–9.29)]
HEU Preconception ART
n = 616
67 [14.6 (11.6–18.3)] 84 [12.9 (10.4–15.9)] 79 [18.2 (14.7–22.3)] 74 [11.1 (8.8–13.9)]
Postconception ART
n = 780
61 [9.5 (7.1–12.5)] 111 [13.7 (11.3–16.5)] 106 [19.2 (15.5–23.5)] 82 [9.9 (7.9–12.4)]
ZDV
n = 873
84 [13.0 (10.4–16.2)] 93 [11.3 (9.1–13.9)] 90 [14.8 (11.9–18.3)] 91 [11.1 (8.9–13.7)]
None
n = 330
39 [18.2 (13.2–24.6)] 51 [16.1 (12.5–20.5)] 30 [13.9 (9.4–20.0)] 43 [13.9 (10.5–18.2)]
Total
N = 2599
251 [12.9 (11.2–14.7)] 339 [13.0 (11.6–14.4)] 305 [16.9 (14.7–19.2)] 290 [11.0 (9.9–12.4)]
Grand total N = 8778 819 [12.5 (11.4–13.7)] 963 [10.7 (10.0–11.5)] 895 [14.9 (13.8–16.1)] 821 [9.2 (8.6–10.0)]
Two hundred five (1.7%) participants had missing data for LBW, 2553 (26.1%) for PTD and 2626 (26.8%) for SGA. 
Abbreviations: ART; antiretroviral treatment, low birthweight; CI: confidence interval; LBW, low birth weight; HEU, HIV-exposed uninfected infants; HUU, HIV-unexposed infants; None, 
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Table 3. Weighted Multivariable Logistic Regression Models for Factors 
Related to Preterm Delivery in (A) HIV-Exposed-Uninfected and HIV-
Unexposed-Uninfected Infants combined and (B) HIV-Exposed-Uninfected 
Infants onlya
Variable
(A) HEU and HUUb 
Combined (B) HEU Onlyc
aOR (95% CI) P Valued
aOR  
(95% CI) P Value
HIV exposure status
 HEU 1.2 (1.0–1.5) .04 ---- ----
 HUU Ref
ARV ---- .04*
 Preconception ART 1.7 (1.1–2.5) .02
 ZDV 1.4 (0.9–2.0) .11
 None 1.9 (1.1–3.1) .01
 Postconception ART Ref
Syphilis serology
 Positive 0.7 (0.4–1.2) .22 0.7 (0.3–1.3) .22
 Negative Ref Ref
Tuberculosis
 Yes 1.1 (0.7–1.9) .65 1.1 (0.5–2.3) .83
 No Ref Ref
Maternal age, years .08* .08*
 20–25 0.9 (0.7–1.1) .36 1.5 (0.7–3.2) .31
 26–29 0.9 (0.7–1.3) .63 1.5 (0.7–3.5) .35
 30–35 0.7 (0.5–0.9) .02 1.0 (0.5–2.3) .94
 >35 1.0 (0.6–1.4) .79 2.0 (0.9–4.6) .11
 <20 Ref Ref
Parity .20* .08*
 2–3 0.8 (0.7–1.0) .06 0.7 (0.4–0.9) .02
 4+ 0.9 (0.6–1.2) .40 0.7 (0.4–1.2) .14
 1 Ref Ref
Maternal education
 ≤ grade 7 1.4 (1.1–1.7) <.01 1.1 (0.8–1.6) .62
 > grade 7 Ref Ref
ANC visits
 +5 0.7 (0.6–0.9) <.01 0.7 (0.5–1.0) .08




 Poorest 1.7 (1.2–2.5) <.01 3.0 (1.3–6.8) <.01
 Second 1.2 (0.9–1.7) .26 1.7 (0.7–3.8) .24
 Third 1.3 (1.0–1.8) 1.00 2.6 (1.2–5.9) .02
 Fourth 1.1 (0.8–1.5) .68 2.1 (0.9–4.4) .07
 Least poor Ref Ref
Household food insecurity
Yes 0.8 (0.6–1.0) .07 1.0 (0.6–1.5) .82
No Ref Ref
Infant race <.01* .41*
 Colored 1.7 (1.3–2.3) <.01 1.4 (0.7–2.7)
 Other 1.3 (0.5–3.4) .56 ----
 Black Ref Ref
Infant gender
 Male 0.9 (0.8–1.0) .12 1.1 (0.8–1.5) .55
 Female Ref Ref
Abbreviations: ANC, antenatal care; aOR, adjusted odds ratio; ART, antiretroviral therapy; 
ARV, antiretroviral drug; CI, confidence interval; HEU, HIV-exposed-uninfected; HUU, HIV-
unexposed; Ref, reference category; ZDV, Zidovudine.
aThe values in the models are aOR (95% CI). 
bModel included 6214 HIV-exposed and -unexposed infants.
cModel included 1839 HIV-exposed-uninfected infants.
dExcept for the asterisk below, the P values in this table are t test P values. The 5% signif-
icance level was used in all analyses.
*This P value is derived from the joint hypothesis testing adjusted Wald test.
Table  4. Weighted Multivariable Logistic Regression Models for Factors 
Related to Low Birth Weight in (A) HIV-Exposed-Uninfected and HIV-Unexposed-
Uninfected Infants combined and (B) HIV-Exposed-Uninfected Infants onlya
Variable
(A) HEU and HUU 
Combinedb (B) HEU Onlyc
aOR (95% CI) P Valued
aOR  
(95% CI) P Value
HIV exposure status
 HEU 1.6 (1.3–1.9) <.01 ----
 HUU Ref
ARV ---- .27*
 Preconception ART ---- 0.9 (0.6–1.3) .54
 ZDV 0.8 (0.6–1.1) .14
 None 1.1 (0.8–1.6) .47
 Postconception ART Ref
Syphilis serology
 Positive 0.8 (0.5–1.3) .29 0.6 (0.3–1.2) .15
 Negative Ref Ref
Tuberculosis
 Yes 1.6 (1.0–2.5) .03 1.3 (0.7–2.6) .46
 No Ref Ref
Maternal age, years <.01* .02*
 20–25 0.8 (0.6–1.0) .02 1.0 (0.5–1.9) .95
 26–29 0.6 (0.5–0.8) <.01 0.8 (0.4–1.6) .59
 30–35 0.6 (0.4–0.8) <.01 0.7 (0.4–1.5) .38
 >35 0.9 (0.6–1.2) .49 1.5(0.7–3.0) .28
 <20 Ref Ref
Parity .45* .40*
 2–3 1.0 (0.8–1.2) .87 0.9 (0.6–1.2) .46
 4+ 0.8 (0.6–1.1) .23 0.7 (0.4–1.2) .18
 1 Ref Ref
Maternal education
 ≤grade 7 1.3 (1.0–1.6) .03 1.0 (0.7–1.4) .98
 >grade 7 Ref Ref
ANC visits
 +5 0.8 (0.6–0.9) .01 0.7 (0.5–1.0) .07




 Poorest 1.1 (0.8–1.5) .66 1.2 (0.6–2.1) .66
 Second 1.2 (0.9–1.7) .20 1.1 (0.6–2.1) .78
 Third 1.5 (1.1–2.0) .01 1.5 (0.8–2.8) .22
 Fourth 1.3 (0.9–1.7) .16 1.4 (0.7–2.6) .34
 Least poor Ref Ref
Household food insecurity
 Yes 1.1 (0.9–1.4) .22 1.2 (0.9–1.7) .27
 No Ref Ref
Infant race <.01*
 Colored 2.0 (1.5–2.6) <.01 3.4 (1.8–6.6) <.01
 Other 1.2 (0.5–2.8) .67 ----
Black Ref Ref
Infant gender
 Male 0.8 (0.7–0.9) <.01 0.8 (0.6–1.0) .03
 Female Ref
Abbreviations: ANC, antenatal care; aOR, adjusted odds ratio; ART, antiretroviral therapy; 
ARV, antiretroviral drug; CI, confidence interval; HEU, HIV-exposed-uninfected; HUU, HIV-
unexposed; Ref, reference category; ZDV, Zidovudine.
aThe values in the models are aOR (95% CI). 
bModel included 8476 HIV-exposed and -unexposed infants.
cModel included 2510 HEU infants.
dExcept for the asterisk below, the P values in this table are t test P values. The 5% signif-
icance level was used in all analyses.
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Table 5. Weighted Multivariable Logistic Regression Models for Factors 
Related to Small for Gestational Age in (A) HIV-Exposed-Uninfected and 
HIV-Unexposed-Uninfected Infants combined and (B) HIV-Exposed-
Uninfected Infants onlya
Variable
(A)HEU and HUU 
Combinedb (B)HEU Onlyc
aOR (95% CI) P Valued aOR (95% CI) P Value
HIV exposure status
 HEU 1.3 (1.1–1.6) <.01 ----
 HUU Ref
ARV ---- .14*
 Preconception ART 0.9 (0.6–1.3) .52
 ZDV 0.7 (0.5–1.0) .05
 None 0.7 (0.4–1.1) .08
 Postconception ART Ref
Syphilis serology
 Positive 1.3 (0.8–2.3) .30 1.6 (0.9–2.8) .15
 Negative Ref Ref
Tuberculosis
 Yes 1.3 (0.8–2.1) .31 1.1 (0.6–2.2) .76
 No Ref Ref
Maternal age, years <.01* .03*
 20–25 0.8 (0.6–1.0) .10 0.8 (0.4–1.5) .45
 26–29 0.6 (0.4–0.8) <.01 0.6 (0.3–1.2) .17
 30–35 0.7 (0.5–1.0) .05 0.6 (0.3–1.2) .15
 >35 1.0 (0.7–1.4) .91 1.2 (0.6–2.5) .66
 <20 Ref Ref
Parity .67* .65*
 2–3 0.9 (0.8–1.1) .42 0.9 (0.7–1.3) .64
 4+ 0.9 (0.6–1.2) .46 0.8 (0.5–1.3) .36
 1 Ref Ref
Maternal education
 ≤grade 7 1.1 (0.9–1.4) .37 1.4 (1.0–2.0) .04
 >grade 7 Ref Ref
ANC visits
 +5 0.8 (0.7–1.0) .02 0.9 (0.7–1.3) .69




 Poorest 1.3 (1.0–1.8) .09 1.3 (0.7–2.3) .41
 Second 1.4 (1.0–1.9) .06 1.2 (0.6–2.3) .60
 Third 1.4(1.0–1.9) .07 1.3 (0.6–2.4) .52
 Fourth 1.3 (0.9–1.8) .14 1.0 (0.5–1.9) .97
 Least poor Ref Ref
Household food insecurity
 Yes 1.0 (0.8–1.3) .87 0.8 (0.6–1.2) .27
 No Ref Ref
Infant race <.01*
 Colored 1.6 (1.3–2.0) <.01 2.1 (1.0–4.4) .04
 Other 1.5 (0.3–7.4) .62 ----
 Black Ref Ref
Infant gender
 Male 1.0 (0.9–1.2) .67 0.9 (0.7–1.2) .60
 Female Ref Ref
Abbreviations: ANC, antenatal care; aOR, adjusted odds ratio; ART, antiretroviral therapy; 
ARV, antiretroviral drug; CI, confidence interval; HEU, HIV-exposed-uninfected; HUU, HIV-
unexposed; Ref, reference category; ZDV, Zidovudine.
aThe values in the models are aOR (95% CI). Only variables that had a significant association 
with low birth weight in the bivariate analysis were included the final multivariable models.
bModel included 6142 HIV-exposed and -unexposed infants.
cModel included 1813 HIV-exposed-uninfected infants.
dExcept for the asterisk below, the P values in this table are t test P values. The 5% signif-
icance level was used in all analyses.
*This P value is derived from the joint hypothesis testing adjusted Wald test.
Table 6. Weighted Multivariable Logistic Regression Models for Factors 
Related to Underweight for Age in (A) HIV-Exposed-Uninfected and HIV-
Unexposed-Uninfected Infants combined and (B) HIV-Exposed-Uninfected 
Infants onlya
Variable
HEU and HUU  
Combinedb HEU Onlyc
aOR (95% CI) P Valued aOR (95% CI) P Value
HIV exposure status ----
 HEU 1.5 (1.2–1.8) <.01
 HUU Ref
ARV .43*
 Preconception ART ---- 1.1 (0.7–1.6) .78
 ZDV 1.1 (0.8–1.6) .64
 None 1.4 (0.9–2.2) .12
 Postconception ART Ref
Syphilis serology
 Positive 0.7 (0.4–1.1) .12 0.5 (0.3–1.0) .05
 Negative Ref Ref
Tuberculosis
 Yes 1.8 (1.2–2.8) <.01 1.8 (1.0–3.2) .04
 No Ref Ref
Maternal age, years .04* .15*
 20–25 0.8 (0.6–1.0) .06 0.8 (0.4–1.4) .34
 26–29 0.7 (0.5–0.9) .01 0.7 (0.4–1.3) .30
 30–35 0.7 (0.5;0.9) .02 0.7 (0.4–1.3) .21
 >35 0.9 (0.6–1.3) .48 1.1 (0.6–2.2) .72
 <20 Ref Ref
Parity .33* .62*
 2–3 0.9 (0.7–1.1) .15 0.9 (0.6–1.3) .52
 4+ 0.8 (0.6–1.2) .27 0.8 (0.4–1.4) .33
 1 Ref Ref
Maternal education
 ≤7 1.4 (1.1–1.8) <.01 1.20 (0.8–1.7) .32
 >7 Ref Ref
ANC visits
 +5 0.8 (0.6–1.0) .02 0.9 (0.6–1.2) .31




 Poorest 1.5 (1.1–2.0) .02 1.4 (0.8–2.7) .25
 Second 1.2 (0.9–1.7) .23 1.2 (0.6–2.4) .58
 Third 1.6 (1.2–2.1) <.01 1.6 (0.8–2.9) .16
 Fourth 1.2 (0.9–1.6) .32 1.3 (0.7–2.5) .38
 Least poor Ref Ref
Household food insecurity
 Yes 1.2 (0.9–1.5) .14 1.1 (0.8–1.6) .63
 No Ref Ref
Delivery method
 C-section 1.4 (1.1–1.7) <.01 1.4 (1.0–1.9) .03
 Vaginal Ref Ref
Infant race <.01*
 Colored 2.2 (1.6–2.8) <.01 2.6 (1.4–5.0) <.01
 Other 1.3 (0.5–3.5) .67 ----
 Black Ref Ref Ref
Infant gender
 Male 1.2 (1.0–1.4) .04 1.4 (1.0–1.8) .04
 Female Ref Ref Ref
Feeding
 Breastfed 0.8 (0.6–1.0) .05 1.1 (0.8–1.5) .56
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regimen. However, data do show that there is no significant dif-
ference in PTD between infants exposed to TDF-containing ART 
and other combinations [45] although a greater risk of PTD has 
been reported with protease-inhibitor compared with nucleo-
side-reverse-transcriptase-based ART [46, 47]. Furthermore, 
some women initiated on ART precenception may have been 
on different ART regimens, probably second-line treatment due 
to drug resistance or poor adherance, than women started post-
concepton. Although self-reported CD4 cell count data were also 
available, we did not include them in the final analysis as the exact 
timing of the CD4 count testing was unknown, many mothers 
did not know their results, and those who had the information 
only reported 1 result. The lack of CD4 cell count and viral load 
data precluded the extent to which the effect of maternal immune 
suppression and viremia, respectively, could be assessed. We also 
could not stratify the ARV analyses by CD4 categories in order to 
minimize bias by indication. Second, as this was an observational 
study, we could not establish causal relationships. Nevertheless, 
in an effort to minimize bias, we included, based on a concep-
tual framework, factors known to influence our outcomes in the 
multivariable analyses. Third, we obtained gestational age from 
the infant’s health card, which contained LMP-based gestational 
age data. While this method remains the most commonly used 
method in SA, it has several limitations, including poor recall 
of the date of LMP and a tendancy to overestimate PTD [48]. 
However, evidence suggests that LMP is a fairly reliable meas-
ure of gestational age in resource-limited settings [49]. We also 
used routinely collected infant weight data, which are subject to 
measurement error. Fourth, in accordance with the 2010 WHO 
PMTCT guidelines, HIV-positive pregnant women who were not 
eligible for ART were started on ZDV from 14 weeks of gesta-
tion to ensure sufficient drug exposure time by late pregnancy 
[50] as this period carries the highest risk of MTCT [51]. Eligible 
HIV-positive pregnant women were, however, started on ART 
immediately in order to improve maternal health and reduce 
MTCT. We were therefore concerned about potential lead time 
bias when comparing the outcomes of the ZDV versus ART HEU 
infants. Although an analysis of our data revealed that the time of 
exposure to the drugs was similar between the ARV groups, we 
restricted the ZDV versus ART comparisons to women who ini-
tiated ART postconception to minimize this bias. Last, selection 
bias is possible as sick infants needing emergency care, infants 
who died before the 6-week clinic visit, and infants attending 
small remote facilities were excluded. As these infants represent 
particularly vulnerable groups, our estimates of LBW, SGA, PTD, 
and UFA could be underestimated.
Notwithstanding these limitations, our study has several 
strengths. First, this is the largest nationally representitve study 
of birth outcomes and growth to date among HEU and HUU 
infants in SA, although it has inherent cross-sectional study 
limitations related to temporality. Second, the availability of 
laboratory HIV-1 enzyme-linked immunosorbent assay and 
PCR results enabled us to exclude HIV-infected infants from 
the analyses, although NVP exposure may cause false-negative 
results [52]. Third, we collected data, although not exhaustive 
data, on maternal, infant, and health system characteristics, 
which enabled us to explore the independent effect of these 
factors and adjust for them as potential confounders. Fourth, 
we estimated birthweight-for-gestational age z scores using the 
recent Intergrowth standard for term- and preterm-born infants. 
Last, we collected data before the wide-scale implementation of 
Option-B+ in SA, which enabled us to compare outcomes of in 
utero ZDV-exposed versus ART-exposed infants.
In conclusion, there was an association between precon-
ception ART and PTD. As ART access increases, pregnancy 
registers or similar routine surveillance should be in place to 
monitor outcomes to inform future policy.
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Variable
HEU and HUU  
Combinedb HEU Onlyc
aOR (95% CI) P Valued aOR (95% CI) P Value
Diarrhea
 Yes 1.9 (1.3–2.8) <.01 1.8 (0.8–4.0) .18
 No Ref Ref
Abbreviations: ANC, antenatal care; aOR, adjusted odds ratio; ART, antiretroviral therapy; 
ARV, antiretroviral drug; CI, confidence interval; HEU, HIV-exposed-uninfected; HUU, HIV-
unexposed; Ref, reference category; ZDV, Zidovudine.
aThe values in the models are aOR (95% CI). Only variables that had a significant association 
with low birth weight in the bivariate analysis were included the final multivariable models.
bModel included 8202 HIV-exposed and -unexposed infants.
cModel included 2414 HIV-exposed-uninfected infants.
dExcept for the asterisk below, the P values in this table are t test P values. The 5% signif-
icance level was used in all analyses.
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